We

prepared the condensed consolidated financial statements following the

requirements of the Securities and Exchange Commission (SEC) for interim

reporting. As permitted under those rules, certain footnotes or other financial

information that are normally required by accounting principles generally

accepted in the United States of America (U.S. GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month and nine-month periods ended

August 23, 2009, and August 24, 2008. Subsequent events have been evaluated

through November 4, 2009.

On

October 15, 2009, we completed our acquisition of Wyeth in a cash-and-stock

transaction valued, based on the closing market price of Pfizer s common stock

on that date, at $50.40 per share of Wyeth common stock, or a total of

approximately $68 billion. We have taken certain actions and incurred certain

costs associated with the transaction prior to the acquisition closing date that

are reflected in our financial statements. However, the assets acquired and

liabilities assumed from Wyeth, the consideration paid to acquire Wyeth, as well

as the results of Wyeth s operations, are not reflected in our Condensed

Consolidated Financial Statements as of and for the three and nine month periods

ended September 27, 2009. See Note 14. Subsequent Event

Acquisition of Wyeth for additional information.

We made

certain reclassifications to prior-period amounts to conform to the

third-quarter and nine-month 2009 presentations related to the presentation of

noncontrolling interests as a result of adopting a new accounting standard (see

Note 2. Adoption of New

Accounting Policies).

Revenues,

expenses, assets and liabilities can vary during each quarter of the year.

Therefore, the results and trends in these interim financial statements may not

be representative of those for the full year.

We are

responsible for the unaudited financial statements included in this

document. The financial statements include all normal and recurring

adjustments that are considered necessary for the fair presentation of our

financial position and operating results.

The

information included in this Quarterly Report on Form 10-Q should be read in

conjunction with the consolidated financial statements and accompanying notes

included in Pfizer s Annual Report on Form 10-K for the year ended December

31, 2008.

Note 2. Adoption of New

Accounting Policies

The

Financial Accounting Standards Board (FASB) has issued FASB Statement

No. 168, The FASB Accounting Standards Codification and the Hierarchy of

Generally Accepted Accounting Principles (Statement 168). Statement 168

establishes the FASB Accounting Standards Codification (Codification) as a

source of authoritative U.S. GAAP recognized by the FASB to be applied by

nongovernmental entities. As a result, these changes will have a significant

impact on how companies reference U.S. GAAP in their financial statements and in

their accounting policies for financial statements issued for interim and annual

periods ending after September 15, 2009. We have begun the

process of implementing the Codification in this quarterly report by providing

references to the Codification topics, as appropriate.

As of

July 1, 2009, we adopted the provisions of FASB Accounting Standards Update

(ASU) No. 2009-5 that provides additional guidance on measuring the fair value

of liabilities in the absence of observable market information, transfer

restrictions and non-performance risk assessment. The adoption of

these provisions did not have a significant impact on our consolidated financial

statements.

As of

March 30, 2009, we adopted the provisions of a new accounting standard issued by

the FASB that amends the guidance for evaluating and measuring

other-than-temporary impairments for available-for-sale or held-to-maturity

debt securities. The adoption of these provisions did not have a significant

impact on our consolidated financial statements.

As of

March 30, 2009, we adopted the provisions of a new accounting standard issued by

the FASB that provide additional guidance for estimating fair value in inactive

markets and the identification of disorderly transactions. We adopted these

provisions prospectively and they did not have a significant impact on our

consolidated financial statements, but could impact the accounting for

acquisitions after adoption, including our acquisition of Wyeth, and other

events, balances and transactions measured at fair value.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As of

January 1, 2009, we adopted several new accounting standards issued by the FASB.

The adoption of these new standards did not have a significant impact on our

consolidated financial statements. In summary, these

provisions:

retain

the purchase method of accounting for acquisitions, but require a number

of changes, including changes in the way assets and liabilities are

recognized in purchase accounting. They also change the recognition of

assets acquired and liabilities assumed arising from contingencies,

require the capitalization of in-process research and development costs at

fair value and require the expensing of acquisition-related costs as

incurred. The adoption of these provisions will impact the accounting for

acquisitions after adoption, including our acquisition of

Wyeth.

amend

the factors considered in developing renewal or extension assumptions used

to determine the useful life of a recognized intangible asset. Among other

things, in the absence of historical experience, an entity will be

required to consider assumptions used by market participants. The adoption

of these provisions could impact the accounting for acquisitions after

adoption, including our acquisition of

Wyeth.

expand

the use of fair value, and related disclosure requirements and specify a

hierarchy of valuation techniques used to develop the fair value measures.

The adoption of these provisions will impact the accounting for

acquisitions after adoption, including our acquisition of Wyeth, and other

events, balances and transactions measured at fair

value.

provide

guidance for the accounting, reporting and disclosure of noncontrolling

interests, previously referred to as minority interests. A noncontrolling

interest represents the portion of equity (net assets) in a subsidiary not

attributable, directly or indirectly, to a parent. The adoption of these

provisions resulted in a number of changes to the presentation of our

consolidated financial statements, but the amounts associated with

noncontrolling interests are not significant. The adoption of these

provisions could impact our accounting for acquisitions after adoption

where we do not acquire 100% of the entity, and our accounting for the

deconsolidations of subsidiaries.

provide

guidance on determining whether an arrangement constitutes a collaborative

arrangement within the scope of the provisions; how costs incurred and

revenues generated on sales to third parties should be reported in the

income statement; how an entity should characterize payments on the income

statement; and what participants should disclose in the notes to the

financial statements about a collaborative arrangement. Accordingly,

additional disclosures are provided in Note 4. Collaborative

Arrangements.

provide

guidance that maintenance deposits paid by a lessee and subsequently

refunded only if a lessee fulfills a maintenance obligation will be

accounted for as a deposit asset.

clarify

how to account for certain transactions involving equity method

investments in areas such as: how to determine the initial carrying value

of the investment; how to allocate the difference between the investor s

carrying value and the investor s share of the underlying equity of the

investment; how to perform an impairment assessment of underlying

intangibles held by the investee; how to account for the investee s

issuance of additional shares; and how to account for an investment on the

cost method when it had been previously accounted for under the equity

method. The adoption of these provisions could impact the accounting for

equity method investments after

adoption.

clarify

the accounting for certain separately identifiable assets, which an

acquirer does not intend to actively use but intends to hold to prevent

its competitors from obtaining access to them. These provisions require an

acquirer to account for a defensive intangible asset as a separate unit of

accounting, which should be amortized to expense over the period the asset

diminishes in value. The adoption of these provisions could impact the

accounting for acquisitions after adoption, including our acquisition of

Wyeth.

Note 3.

Acquisitions

In the

second quarter of 2008, we acquired Encysive Pharmaceuticals Inc. (Encysive), a

biopharmaceutical company whose main asset is Thelin, which is used for the

treatment of pulmonary arterial hypertension. The cost of acquiring Encysive,

through a tender offer and subsequent merger, was approximately

$200 million, including transaction costs. Upon our acquisition of

Encysive, Encysive's change of control repurchase obligations under its

outstanding $130 million 2.5% convertible notes were triggered and, as a result,

Encysive repurchased the convertible notes in consideration for their par value

plus accrued interest in June 2008. In addition, in the second quarter of 2008,

we acquired Serenex, Inc. (Serenex), a privately held biotechnology company,

whose main asset is SNX-5422, an oral Heat Shock Protein 90 (Hsp90) for the

potential treatment of solid tumors and hematological malignancies and an

extensive Hsp90 inhibitor compound library, which has potential uses in treating

cancer, inflammatory and neurodegenerative diseases. In connection with these

acquisitions, through the third quarter of 2008, we recorded approximately $170

million in Acquisition-related

in-process research and development charges and approximately $450

million in intangible assets.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In the

first quarter of 2008, we acquired CovX, a privately held biotherapeutics

company specializing in preclinical oncology and metabolic research and the

developer of a biotherapeutics technology platform. Also in the first quarter of

2008, we acquired all the outstanding shares of Coley Pharmaceutical Group,

Inc., (Coley), a biopharmaceutical company specializing in vaccines and drug

candidates designed to fight certain cancers, allergy and asthma disorders, and

autoimmune diseases, for approximately $230 million. In connection with these

and two smaller acquisitions related to Animal Health, we recorded approximately

$398 million in Acquisition-related in-process

research and development charges during the first nine months of

2008. In the first nine

months of 2009, we resolved a contingency associated with CovX and recorded $20

million in Acquisition-related

in-process research and development charges. We did not consummate any

acquisitions in the first nine months of 2009.

Note 4. Collaborative

Arrangements

In the

normal course of business, we enter into collaborative arrangements with respect

to in-line medicines, as well as medicines in development, that require

completion of research and regulatory approval. Collaborative arrangements are

contractual agreements with third parties that involve a joint operating

activity, typically a research and/or commercialization effort, where both we

and our partner are active participants in the activity and are exposed to the

significant risks and rewards of the activity. Our rights and obligations under

our collaborative arrangements vary. For example, we have agreements to

co-promote pharmaceutical products discovered by other companies, and we have

agreements where we partner to co-develop and/or participate together in

commercializing, marketing, promoting, manufacturing, and/or distributing a drug

product.

Payments

to or from our collaboration partners are presented in the statement of income

based on the nature of the arrangement (including its contractual terms), the

nature of the payments and applicable accounting guidance. Under co-promotion

agreements, we record the amounts received from our partners as alliance

revenues, a component of Revenues, when our

co-promotion partners are the principal in the transaction and we receive a

share in their net sales or profits. Alliance revenues are recorded when our

co-promotion partners ship the product and title passes to their customers.

Expenses for selling and marketing these products are included in Selling, informational and

administrative expenses. In arrangements where we manufacture a product

for our partner, we record revenues when our partner sells the product and title

passes to its customer. All royalty payments to collaboration partners are

recorded as part of Cost of

sales.

The

amounts and classifications of payments (income/(expense)) between us and our

collaboration partners follow:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept.

27,

2009

Sept.

28,

2008

Sept.

27,

2009

Sept.

28,

2008

Revenues

Revenues(a)

131

143

409

369

Revenues

Alliance revenues (b)

692

571

1,872

1,622

Total

Revenues from collaborative arrangements

823

714

2,281

1,991

Cost

of sales (c)

(40

(62

(131

(129

Selling,

informational and administrative expenses(d)

27

38

24

57

Research

and development expenses(e)

(58

(51

(302

(147

(a)

Represents

sales to our partners of products manufactured by

us.

(b)

Substantially

all related to amounts earned from our partners under co-promotion

agreements.

(c)

Primarily

related to royalties earned by our partners and cost of sales associated

with inventory purchased from our

partners.

(d)

Represents

net reimbursements from our partners and reimbursements to our partners

for Selling, informational and administrative expenses

incurred.

(e)

Primarily

related to net reimbursements earned by our partners, except that the

first nine months of 2009 also includes a $150 million milestone payment

to one of our partners.

For the

three months and nine months ended September 27, 2009, Other

(income)/deductions-net, includes income of $20 million paid to us for

the termination of a collaboration agreement.

The

amounts disclosed in the above table do not include transactions with third

parties other than our collaboration partners, or other costs associated with

the products under the collaborative arrangements.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Pfizer

Cost-Reduction Initiatives

The

following costs were incurred in connection with all of our Pfizer

cost-reduction initiatives, which began in 2005, and do not include any amounts

related to Wyeth:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept.

27,

2009

Sept.

28,

2008

Sept.

27,

2009

Sept.

28,

2008

Implementation

costs(a)

80

378

410

1,140

Restructuring

charges(b)

61

338

392

1,077

Total

costs related to our Pfizer cost-reduction initiatives

141

716

802

2,217

(a)

For

the third quarter of 2009, included in Cost of sales ($23

million), Selling,

informational and administrative expenses ($51 million), Research and development

expenses ($5 million), and Other (income)/deductions -

net ($1 million). For the third quarter of 2008, included in Cost of sales ($172

million), Selling,

informational and administrative expenses ($95 million), Research and development

expenses ($108 million) and Other (income)/deductions -

net ($3 million). For the first nine months of 2009, included in

Cost of sales

($144 million), Selling,

informational and administrative expenses ($182 million), Research and development

expenses ($78 million), and Other (income)/deductions -

net ($6 million). For the first nine months of 2008, included in

Cost of sales

($520 million), Selling,

informational and administrative expenses ($270 million), Research and development

expenses ($348 million) and Other (income)/deductions -

net ($2

million).

(b)

Included

in Restructuring charges

and acquisition-related

costs.

From the

beginning of the Pfizer cost-reduction initiatives in 2005 through September 27,

2009, the restructuring charges primarily relate to our supply network

transformation efforts and the restructuring of our worldwide marketing and

research and development operations, and the implementation costs primarily

relate to depreciation arising from the shortening of the useful lives of

certain assets, as well as system and process standardization and the expansion

of shared services.

The

following components of restructuring charges are associated with all of our

Pfizer cost-reduction initiatives, which began in 2005, and do not include any

amounts related to Wyeth:

(millions

of dollars)

Costs

Incurred

Through

Sept.

27, 2009

Activity

Through

Sept.

27, 2009(a)

Accrual

as of

Sept.

27, 2009(b)

Employee

termination costs

5,350

4,245

1,105

Asset

impairments

1,401

1,401

Other

524

438

86

Total

restructuring charges

7,275

6,084

1,191

(a)

Includes

adjustments for foreign currency

translation.

(b)

Included

in Other current

liabilities ($712 million) and Other non-current liabilities

($479

million).

During

the third quarter of 2009, we expensed $36 million for Employee termination costs,

$17 million for Asset

impairments and $8 million for Other. During the first nine

months of 2009 we expensed $200 million for Employee termination costs,

$108 million for Asset

impairments and $84 million for Other. From June 2005 through

September 27, 2009, Employee

termination costs, net of the impact of a change in estimate, represent the expected

reduction of the workforce by approximately 30,900 employees, mainly in

manufacturing, sales and research, and approximately 26,300 of these employees

have been terminated. Employee

termination costs are recorded when the actions are probable and

estimable and include accrued severance benefits, pension and postretirement

benefits. Asset

impairments primarily include charges to write down property, plant and

equipment. Other

primarily includes costs to exit certain activities.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Acquisition-Related

Costs

We

incurred the following acquisition-related costs primarily in connection with

our acquisition of Wyeth:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept.

27,

2009

Sept.

28,

2008

Sept.

27,

2009

Sept.

28,

2008

Transaction

costs (a)

19

572

Pre-integration

costs and other(b)

113

28

242

36

Total

acquisition-related costs(c)

132

28

814

36

(a)

Transaction

costs include banking, legal, accounting and other costs directly related

to our acquisition of Wyeth. Substantially all of the costs incurred to

date are fees related to a $22.5 billion bridge term loan credit agreement

entered into with certain financial institutions on March 12, 2009 to

partially fund our acquisition of Wyeth. The bridge term loan credit

agreement was terminated in June 2009 as a result of our issuance of

approximately $24.0 billion of senior unsecured notes in the first half of

2009. All bridge term loan commitment fees have been expensed, and we are

no longer subject to the covenants under that agreement (see Note 8D: Financial

Instruments: Long-Term

Debt).

(b)

Pre-integration

costs and other in 2009 primarily represent external, incremental costs of

integration planning that are directly related to our acquisition of Wyeth

and include costs associated with preparing for systems and other

integration activities. 2008 amounts relate to other restructuring

charges.

(c)

Included

in Restructuring charges

and acquisition-related

costs.

Note 7. Comprehensive

Income/(Expense)

The

components of comprehensive income/(expense) follow:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept.

27,

2009

Sept.

28,

2008

Sept.

27,

2009

Sept.

28,

2008

Net

income before allocation to noncontrolling interests

2,881

2,284

7,877

7,856

Other

comprehensive income/(expense):

Currency translation adjustment

and other

599

(1,766

2,853

(1,232

Net unrealized gains/(losses)

on derivative financial instruments

(43

13

(210

41

Net unrealized gains/(losses)

on available-for-sale securities

86

(25

312

(39

Benefit plan

adjustments

(459

159

(282

244

Total other comprehensive

gains/(loss)

183

(1,619

2,673

(986

Total

comprehensive income before allocation to

noncontrolling

interests

3,064

665

10,550

6,870

Comprehensive (income)/loss

attributable to

noncontrolling

interests

(8

(11

(31

Comprehensive

income attributable to Pfizer Inc.

3,067

657

10,539

6,839

10

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 8. Financial

Instruments

A. Selected Financial Assets

and Liabilities

Information

about certain of our financial assets and liabilities follows:

(millions

of dollars)

Sept.

27,

2009

Dec.

31,

2008

Selected

financial assets measured at fair value on a recurring basis (a)

Trading securities (b)

181

190

Available-for-sale debt securities

(c)

50,915

30,061

Available-for-sale money market

funds

7,581

398

Available-for-sale equity

securities, excluding money market funds (c)

252

319

Derivative financial instruments

in receivable positions (d)

Interest rate

swaps

370

732

Foreign currency

swaps

670

128

Foreign currency forward-exchange

contracts

489

399

Total

60,458

32,227

Other

selected financial assets (e):

Held-to-maturity debt

securities, carried at amortized cost (c)

3,779

2,349

Short-term loans, carried at

cost

791

824

Long-term loans, carried at

cost

1,194

1,568

Private equity securities,

carried at cost

150

182

Total

5,914

4,923

Total

selected financial assets

66,372

37,150

Financial

liabilities measured at fair value on a recurring basis (a):

Derivative financial instruments

in a liability position (f):

Interest rate

swaps

Foreign currency

swaps

647

153

Foreign currency forward-exchange

contracts

1,020

1,083

Total

1,675

1,243

Other

financial liabilities (e) ,

(g):

Short-term borrowings, carried at

historical proceeds, as adjusted (h)

6,954

9,320

Long-term debt, carried at

historical proceeds, as adjusted (i)

32,402

7,963

Total

39,356

17,283

Total

selected financial liabilities

41,031

18,526

(a)

Fair

values are determined based on valuation techniques categorized as

follows: Level 1 means the use of quoted prices for identical instruments

in active markets; Level 2 means the use of quoted prices for

similar instruments in active markets or quoted prices for identical or

similar instruments in markets that are not active or are directly or

indirectly observable; Level 3 means the use of unobservable inputs.

Virtually all of our financial assets and liabilities measured at fair

value on a recurring basis use Level 2 inputs in the calculation of fair

value, except that included in available-for-sale equity securities,

excluding money market funds, are $159 million as of September 27, 2009

and $87 million as of December 31, 2008 of investments that use Level 1

inputs in the calculation of fair value. None of our financial assets and

liabilities measured at fair value on a recurring basis are valued based

on Level 3 inputs at September 27, 2009 or December 31,

2008.

(b)

Trading

securities are held in trust for legacy Pharmacia severance

benefits.

(c)

Gross

unrealized gains and losses are not

significant.

(d)

Designated

as hedging instruments except for certain foreign currency contracts used

as offsets, namely, foreign currency swaps with fair values of $159

million and foreign currency forward-exchange contracts with fair values

of $67 million at September 27, 2009; and foreign currency

forward-exchange contracts with fair values of $175 million and foreign

currency swaps with fair values of $32 million at December 31,

2008.

(e)

The

differences between the estimated fair values and carrying values of our

financial assets and liabilities not measured at fair value on a recurring

basis were not significant as of September 27, 2009 or December 31,

2008.

(f)

Designated

as hedging instruments except for certain foreign currency contracts used

as offsets, namely, foreign currency forward-exchange contracts with fair

values of $160 million at September 27, 2009; and foreign currency

forward-exchange contracts with fair values of $836 million and foreign

currency swaps with fair values of $76 million at December 31,

2008.

(g)

The

carrying amounts may include adjustments for discount or premium

amortization or for the effect of interest rate swaps designated as

hedges.

(h)

Includes

foreign currency borrowings with fair values of $1.1 billion at September

27, 2009 and $1.6 billion at December 31, 2008, which are used as hedging

instruments.

(i)

Includes

foreign currency debt with fair values of $2.1 billion at September 27,

2009 and December 31, 2008, which is used as a hedging

instrument.

11

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The

following methods and assumptions were used to estimate the fair value of our

financial assets and liabilities: